T1	Disease	68 96	non-small cell lung cancer (
T2	Disease	97 114	NSCLC ) confirmed
T3	Pharmacodynamic_phenotype	128 145	response rate and
T4	Phenotype	146 174	progression-free survival of
T5	Gene_or_protein	181 248	epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor
T6	Chemical	181 257	epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor as first
T7	Chemical	285 309	chemotherapy in patients
T8	Limited_variation	341 342	.
R1	isEquivalentTo	Arg1:T1	Arg2:T2
R2	isEquivalentTo	Arg1:T2	Arg2:T1
R3	increases	Arg1:T2	Arg2:T3
R4	increases	Arg1:T2	Arg2:T4
R5	increases	Arg1:T3	Arg2:T4
R6	isAssociatedWith	Arg1:T3	Arg2:T8
R7	isAssociatedWith	Arg1:T4	Arg2:T2
R8	isAssociatedWith	Arg1:T4	Arg2:T3
R9	isAssociatedWith	Arg1:T4	Arg2:T7
R10	isAssociatedWith	Arg1:T4	Arg2:T8
R11	treats	Arg1:T5	Arg2:T1
R12	treats	Arg1:T5	Arg2:T2
R13	increases	Arg1:T5	Arg2:T3
R14	increases	Arg1:T5	Arg2:T4
R15	influences	Arg1:T5	Arg2:T6
R16	treats	Arg1:T5	Arg2:T8
R17	treats	Arg1:T6	Arg2:T1
R18	treats	Arg1:T6	Arg2:T2
R19	increases	Arg1:T6	Arg2:T3
R20	increases	Arg1:T6	Arg2:T4
R21	influences	Arg1:T6	Arg2:T5
R22	influences	Arg1:T6	Arg2:T7
R23	treats	Arg1:T6	Arg2:T8
R24	treats	Arg1:T7	Arg2:T1
R25	treats	Arg1:T7	Arg2:T2
R26	influences	Arg1:T7	Arg2:T5
R27	influences	Arg1:T7	Arg2:T6
R28	isAssociatedWith	Arg1:T7	Arg2:T8
R29	isAssociatedWith	Arg1:T8	Arg2:T1
R30	isAssociatedWith	Arg1:T8	Arg2:T2
R31	influences	Arg1:T8	Arg2:T3
R32	influences	Arg1:T8	Arg2:T4
R33	influences	Arg1:T8	Arg2:T5
R34	influences	Arg1:T8	Arg2:T6
R35	isAssociatedWith	Arg1:T8	Arg2:T7
